Stockscreener 앱 받기
8.33
23.96%
1.61
시장 영업 전:
6.48
-1.85
-22.21%
전일 마감가:
$6.72
열려 있는:
$6.82
하루 거래량:
7.48M
Relative Volume:
5.28
시가총액:
$537.87M
수익:
$317.00K
순이익/손실:
$-53.47M
주가수익비율:
-4.4074
EPS:
-1.89
순현금흐름:
$-49.31M
1주 성능:
+26.60%
1개월 성능:
+30.16%
6개월 성능:
+105.68%
1년 성능:
+252.97%
1일 변동 폭
$6.77
$8.48
1주일 범위
$6.26
$8.48
52주 변동 폭
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
명칭
Immuneering Corp
전화
617-500-8080
주소
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
IMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
8.33 | 433.91M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 개시 | Leerink Partners | Outperform |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2024-03-15 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 개시 | Needham | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-04-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 개시 | Mizuho | Neutral |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 개시 | Chardan Capital Markets | Buy |
| 2022-04-01 | 개시 | Oppenheimer | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
모두보기
Immuneering Corp 주식(IMRX)의 최신 뉴스
Stock Market Today: S&P 500, Dow Jones Futures Decline — AZZ, Northrop Grumman, Immuneering In Focus - Benzinga
IMRX: Atebumetanib plus chemo showed 64% 12-month survival in pancreatic cancer, nearly double standard care - TradingView — Track All Markets
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha
Immuneering reports 64% survival rate in pancreatic cancer trial - Investing.com
Immuneering stock falls after reporting survival data for pancreatic cancer drug - Investing.com
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data - TipRanks
Immuneering reports 64% survival rate in pancreatic cancer trial By Investing.com - Investing.com Canada
Immuneering Corp Announces Interim Data from Phase 2a Trial - TradingView — Track All Markets
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - The Manila Times
Immuneering reports 64% survival rate at 12 months for pancreatic cancer drug - StreetInsider
Immuneering signals fiscal strategy with atebimetinib trial progress - Traders Union
Retail Trends: Will Immuneering Corporation stock see insider buyingCEO Change & Detailed Earnings Play Strategies - moha.gov.vn
All you need to know about Immuneering (IMRX) rating upgrade to buy - MSN
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 - Seeking Alpha
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy - Yahoo Finance
Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19% - Sahm
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP - TipRanks
Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial - Nasdaq
Immuneering to provide 12-month survival data for pancreatic cancer drug - Investing.com
Immuneering to provide 12-month survival data for pancreatic cancer drug By Investing.com - Investing.com South Africa
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 - The Manila Times
Wall Street Zen Downgrades Immuneering (NASDAQ:IMRX) to Sell - MarketBeat
Can Immuneering Corporation stock outperform in 2025 bull marketWeekly Trend Report & Long-Term Growth Plans - Улправда
Immuneering on track to dose first patient in pancreatic cancer trial in 2026 - MSN
Pancreatic cancer treatment atebimetinib set for Phase 3 trial - Rare Cancer News
Is Immuneering Corporation stock attractive for income investorsJuly 2025 Update & Stepwise Trade Signal Guides - Улправда
Why Immuneering Corporation stock attracts global investorsGlobal Markets & Accurate Buy Signal Notifications - Улправда
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA - The Manila Times
Immuneering to begin Phase 3 trial of pancreatic cancer drug mid-2026 - Investing.com Australia
Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026 - Nasdaq
Immuneering stock rises after FDA and EMA align on Phase 3 trial design By Investing.com - Investing.com South Africa
Immuneering stock rises after FDA and EMA align on Phase 3 trial design - Investing.com
Global trial to test drug combo for first-line pancreatic cancer patients - Stock Titan
Immuneering to be added to the Nasdaq Biotechnology Index - TipRanks
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Immuneering (Nasdaq: IMRX) to be added to Nasdaq Biotechnology Index on Dec. 22 - Stock Titan
Analyst Confidence Buoys Immuneering’s Clinical Prospects - AD HOC NEWS
Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Sahm
Top investors say Immuneering Corp (IMRX) ticks everything they need - setenews.com
You Should Read This Analysis Before Investing in Immuneering Corp (NASDAQ:IMRX) - uspostnews.com
This trade activity should not be overlooked: Immuneering Corp (IMRX) - setenews.com
Immuneering (IMRX) Stock Analysis Report | Financials & Insights - Benzinga
Will Immuneering Corporation stock see insider buying2025 Earnings Surprises & Stock Timing and Entry Methods - moha.gov.vn
We Think Immuneering (NASDAQ:IMRX) Can Afford To Drive Business Growth - Yahoo Finance
Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? - Yahoo Finance
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Immuneering Corporation (IMRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A new trading data show Immuneering Corp (IMRX) is showing positive returns. - Setenews
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - simplywall.st
Immuneering Corp (IMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):